pentamidine isethionate
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- pentamidine isethionate
- Generic name
- PENTAMIDINE ISETHIONATE
- Manufacturer
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 5c14fbf2-e21f-44b3-b35c-06919d40d7e0
- SPL ID
- 77269af7-78f2-4f7d-bfe9-bdcd2bedaa86
- Version
- 7
- Effective date
- 2025-10-31
- Source export date
- 2026-09-28
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/aa96b5a2be6b394393acd0090f6948bdf99e0e8e00666f81608929c8fa83db77/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:16:46
| Harmonized routes |
|---|
| INTRAMUSCULAR, INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 213806 | derived:openfda.application_number |
| application number | ANDA213806 | openfda.application_number | |
| brand name | pentamidine isethionate | openfda.brand_name | |
| generic name | PENTAMIDINE ISETHIONATE | openfda.generic_name | |
| manufacturer name | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 23155-748-31 | openfda.package_ndc |
| ndc | package | 23155-748-41 | openfda.package_ndc |
| ndc | product | 23155-748 | openfda.product_ndc |
| ndc11 | package | 23155074841 | derived:openfda.package_ndc |
| ndc11 | package | 23155074831 | derived:openfda.package_ndc |
| rxcui | 861601 | openfda.rxcui | |
| spl id | 77269af7-78f2-4f7d-bfe9-bdcd2bedaa86 | id | |
| spl set id | 5c14fbf2-e21f-44b3-b35c-06919d40d7e0 | set_id | |
| unii | V2P3K60DA2 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Severe hypotension may result after a single IM or IV dose and is more likely with rapid IV administration (see PRECAUTIONS ). The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated. Patients should be closely monitored for the development of serious adverse reactions (see PRECAUTIONS and ADVERSE REACTIONS ). Extravasations have been reported which, in some instances, proceeded to ulceration, tissue necrosis and/or sloughing at the injection site. While not common, surgical debridement and skin grafting has been necessary in some of these cases; long-term sequelae have been reported. Prevention is the most effective means of limiting the severity of extravasation. The intravenous needle or catheter must be properly positioned and closely observed throughout the period of pentamidine isethionate administration. If extravasation occurs, the injection should be discontinued immediately and restarted in another vein. Because there are no known local treatment measures which have proven to be useful, management of the extravasation should be symptomatic.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS CAUTION : Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Nephrotoxic events (increased creatinine, impaired renal function, azotemia, and renal failure) are common with the parenteral administration of pentamidine isethionate. The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated. The most frequently reported spontaneous adverse events (1 to 30%) reported in clinical trials, regardless of their relation to pentamidine isethionate therapy were as follows (n=424): Cardiovascular: Hypotension 5.0% Gastrointestinal: Anorexia/Nausea 5.9% Hematologic: Anemia 1.2% Leukopenia 10.4% Thrombocytopenia 2.6% Hepatic: Elevated liver function tests 8.7% Metabolic: Hypoglycemia 5.9% Neurologic: Confusion/hallucinations 1.7% Skin: Sterile abscess and/or necrosis, pain, or induration at the site of IM injection 11.1% Rash 3.3% Special Senses: Bad taste 1.7% Urogenital: Azotemia 8.5% Elevated serum creatinine 23.6% Elevated blood urea nitrogen 6.6% Impaired renal function 28.8% Adverse events with a frequency of less than 1% incidence were as follows (No causal relationship to treatment has been established for these adverse events): Body as a whole: Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome. Cardiovascular: Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia. Gastrointestinal: Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting. Hematological: Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time. Hepatic: Hepatic dysfunction, hepatitis and hepatomegaly Metabolic: Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia. Neurological: Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo. Respiratory system: Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea. Skin: Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria. Special senses: Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell. Urogenital: Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure. From post-marketing clinical experience with pentamidine isethionate, the following adverse events have been reported: cough, diabetes mellitus/ketoacidosis, dyspnea, infiltration (extravasation–see WARNINGS ), and torsades de pointes.
adverse reactions table
<table ID="ID39" width="562" styleCode="Noautorules"><col width="328"/><col width="234"/><tbody><tr><td valign="top" styleCode="Lrule Toprule Rrule" align="left"> Cardiovascular: </td><td valign="top" styleCode=" Toprule Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypotension </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 5.0% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Gastrointestinal: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anorexia/Nausea </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 5.9% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Hematologic: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Anemia </td><td valign="top" styleCode=" Rrule" align="left"> 1.2% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Leukopenia </td><td valign="top" styleCode=" Rrule" align="left"> 10.4% </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Thrombocytopenia </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 2.6% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Hepatic: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Elevated liver function tests </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 8.7% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Metabolic: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypoglycemia </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 5.9% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Neurologic: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Confusion/hallucinations </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 1.7% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Skin: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Sterile abscess and/or necrosis, pain, or induration at the site of IM injection </td><td valign="top" styleCode=" Rrule" align="left"> 11.1% </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Rash </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 3.3% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Special Senses: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Bad taste </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 1.7% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Urogenital: </td><td valign="top" styleCode=" Rrule"/></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Azotemia </td><td valign="top" styleCode=" Rrule" align="left"> 8.5% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Elevated serum creatinine </td><td valign="top" styleCode=" Rrule" align="left"> 23.6% </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Elevated blood urea nitrogen </td><td valign="top" styleCode=" Rrule" align="left"> 6.6% </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Impaired renal function </td><td valign="top" styleCode=" Botrule Rrule" align="left"> 28.8% </td></tr></tbody></table>
adverse reactions table
<table ID="ID41" width="708" styleCode="Noautorules"><col width="113"/><col width="595"/><tbody><tr><td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Body as a whole: </td><td valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cardiovascular: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Gastrointestinal: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hematological: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hepatic: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Hepatic dysfunction, hepatitis and hepatomegaly </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Metabolic: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Neurological: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Respiratory system: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Skin: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Special senses: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell. </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Urogenital: </td><td valign="top" styleCode=" Botrule Rrule" align="left"> Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure. </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.